文献速递肿瘤 PET/CT

P-Score在前瞻性DEPROMP队列中的外部验证:整合mpMRI与PSMA PET/CT的前列腺癌风险分层

External validation of the P-Score in the prospective, pre-biopsy DEPROMP cohort: integrated mpMRI and PSMA PET/CT risk stratification for prostate cancer detection.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-07-16

DEPROMP前瞻性队列纳入230例未活检的可疑前列腺癌男性,行多参数MRI与[68Ga]Ga-DKFZ-PSMA-11 PET/CT,以靶向活检病理为参考标准外部验证整合PI-RADS与PRIMARY评分的P-Score。结果显示P-Score对ISUP≥2的AUC为0.796,与PI-RADS(0.804)无显著差异,但显著优于PRIMARY评分(0.730)。

要点

  • P-Score对临床显著前列腺癌的诊断效能与PI-RADS相当。
  • P-Score对ISUP≥2的AUC显著高于PRIMARY评分。
  • PI-RADS 3亚组中P-Score与PRIMARY评分诊断效能均有限。

核心结论

  • P-Score在该外部验证队列中诊断效能与PI-RADS相当,尚需进一步研究确定其在特定临床场景与前瞻性研究中的角色。

研究设计与样本

  • 前瞻性DEPROMP试验纳入230例未活检的可疑前列腺癌男性,行多参数MRI与[68Ga]Ga-DKFZ-PSMA-11 PET/CT,以靶向活检组织病理为参考标准。
  • 采用PI-RADS v2.1、PRIMARY评分及衍生的P-Score评估病灶,并以ROC曲线分析与DeLong检验比较各评分系统的AUC。

主要发现

  • 对ISUP≥2前列腺癌,P-Score的AUC为0.796,与PI-RADS的0.804无显著差异(p=0.72),显著优于PRIMARY评分的0.730(p<0.001)。
  • 对ISUP≥3前列腺癌,P-Score的AUC为0.840,与PI-RADS的0.830无显著差异(p=0.66)。
  • PI-RADS 3亚组中P-Score的AUC为0.573(95%CI:0.407-0.739),PRIMARY评分为0.556(95%CI:0.389-0.722)。

关键数值与推荐

  • P-Score对ISUP≥2的AUC为0.796,PI-RADS为0.804(p=0.72),PRIMARY评分为0.730(p<0.001)。
  • P-Score对ISUP≥3的AUC为0.840,PI-RADS为0.830(p=0.66)。
  • PI-RADS 3亚组P-Score的AUC为0.573(95%CI:0.407-0.739)。

临床怎么用

  • 可将P-Score作为整合解剖与分子影像的标准化评分框架用于前列腺癌风险分层,但其相比PI-RADS的增量价值尚待进一步研究确定。

局限性

  • PI-RADS 3亚组的诊断效能有限,P-Score与PRIMARY评分的AUC均较低。
  • 作者指出尚需进一步研究确定P-Score在特定临床场景与前瞻性研究中的角色。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to externally validate the P-Score, a composite scoring system combining PI-RADS and PRIMARY score, for its diagnostic accuracy in detecting clinically significant (ISUP ≥ 2) and higher-grade (ISUP ≥ 3) prostate cancer (PCa). METHODS: 230 biopsy-naïve men with suspected PCa were prospectively enrolled in the DEPROMP trial and underwent multiparametric MRI and [68Ga]Ga-DKFZ-PSMA-11 PET/CT. Lesions were assessed using PI-RADS v2.1, the PRIMARY score, and the derived P-Score. Targeted biopsies were guided by imaging findings, and histopathology served as the reference standard. Diagnostic performance was evaluated using receiver operating characteristic curve analyses and DeLong's test to compare the area under the curve (AUC) between scoring systems. RESULTS: For clinically significant PCa (ISUP ≥ 2), no significant difference in diagnostic performance was observed between the P-Score (AUC 0.796) and PI-RADS (AUC 0.804; p = 0.72), whereas the P-Score significantly outperformed the PRIMARY score (AUC 0.730; p < 0.001). Similarly, for detection of ISUP ≥ 3 disease, no significant difference in diagnostic performance was observed between the P-Score (AUC 0.840) and PI-RADS (AUC 0.830; p = 0.66). In the PI-RADS 3 subgroup, diagnostic performance remained limited, with AUCs of 0.573 (95% CI: 0.407-0.739) for the P-Score and 0.556 (95% CI: 0.389-0.722) for the PRIMARY score. Overall, the P-Score demonstrated robust diagnostic performance across disease categories and showed comparable accuracy to PI-RADS. CONCLUSION: The P-Score demonstrated diagnostic performance comparable to PI-RADS in this external validation cohort. While providing a standardized framework integrating anatomical and molecular imaging findings, further studies are warranted to determine whether it has a role in selected clinical scenarios and prospective research settings.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Schmidt CJ, Gaertner FC, Kreppel B, et al. External validation of the P-Score in the prospective, pre-biopsy DEPROMP cohort: integrated mpMRI and PSMA PET/CT risk stratification for prostate cancer detection. Eur J Nucl Med Mol Imaging. 2026. PMID: 42458057. doi:10.1007/s00259-026-08073-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。